{(R)-1-[(R)-7-(tert-Butyl-diphenyl-silanyloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-2-oxo-pyrrolidin-3-yl}-carbamic acid tert-butyl ester | 1026622-43-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: {(R)-1-[(R)-7-(tert-Butyl-diphenyl-silanyloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-2-oxo-pyrrolidin-3-yl}-carbamic acid tert-butyl ester
• 英文别名: tert-butyl N-[(3R)-1-[(1R)-7-[tert-butyl(diphenyl)silyl]oxy-1,2,3,4-tetrahydronaphthalen-1-yl]-2-oxopyrrolidin-3-yl]carbamate
• CAS: 1026622-43-4
• 化学式: C₃₅H₄₄N₂O₄Si
• 分子量: 584.831
• InChiKey: IANTUTFKRXEURW-FIRIVFDPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.13
• 重原子数：
  42
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  67.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  {(R)-1-[(R)-7-(tert-Butyl-diphenyl-silanyloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-2-oxo-pyrrolidin-3-yl}-carbamic acid tert-butyl ester 在 sodium cyanoborohydride 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 4-[5-({(R)-1-[(R)-7-(tert-Butyl-diphenyl-silanyloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-2-oxo-pyrrolidin-3-ylamino}-methyl)-imidazol-1-ylmethyl]-2-fluoro-benzonitrile
  参考文献：
  名称：

  3-Aminopyrrolidinone Farnesyltransferase Inhibitors:  Design of Macrocyclic Compounds with Improved Pharmacokinetics and Excellent Cell Potency

  摘要：

  A series of macrocyclic 3-aminopyrrolidinone farnesyltransferase inhibitors (FTIs) has been synthesized. Compared with previously described linear 3-aminopyrrolidinone FTIs such as compound 1, macrocycles such as 49 combined improved pharmacokinetic properties with a reduced potential for side effects. In dogs, oral bioavailability was good to excellent, and increases in plasma half-life were due to attenuated clearance. It was observed that in vivo clearance correlated with the flexibility of the molecules and this concept proved useful in the design of FTIs that exhibited low clearance, such as FTI 78. X-ray crystal structures of compounds 49 and 66 complexed with farnesyltransferase (FTase)-farnesyl diphosphate (FPP) were determined, and they provide details of the key interactions in such ternary complexes. Optimization of this 3-aminopyrrolidinone series of compounds led to significant increases in potency, providing 83 and 85, the most potent inhibitors of FTase in cells described to date.

  DOI：

  10.1021/jm010531d
• 作为产物：
  描述：

  {(R)-3-tert-Butoxycarbonylamino-3-[(R)-7-(tert-butyl-diphenyl-silanyloxy)-1,2,3,4-tetrahydro-naphthalen-1-ylcarbamoyl]-propyl}-dimethyl-sulfonium; iodide 在 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 生成 {(R)-1-[(R)-7-(tert-Butyl-diphenyl-silanyloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-2-oxo-pyrrolidin-3-yl}-carbamic acid tert-butyl ester
  参考文献：
  名称：

  3-Aminopyrrolidinone Farnesyltransferase Inhibitors:  Design of Macrocyclic Compounds with Improved Pharmacokinetics and Excellent Cell Potency

  摘要：

  A series of macrocyclic 3-aminopyrrolidinone farnesyltransferase inhibitors (FTIs) has been synthesized. Compared with previously described linear 3-aminopyrrolidinone FTIs such as compound 1, macrocycles such as 49 combined improved pharmacokinetic properties with a reduced potential for side effects. In dogs, oral bioavailability was good to excellent, and increases in plasma half-life were due to attenuated clearance. It was observed that in vivo clearance correlated with the flexibility of the molecules and this concept proved useful in the design of FTIs that exhibited low clearance, such as FTI 78. X-ray crystal structures of compounds 49 and 66 complexed with farnesyltransferase (FTase)-farnesyl diphosphate (FPP) were determined, and they provide details of the key interactions in such ternary complexes. Optimization of this 3-aminopyrrolidinone series of compounds led to significant increases in potency, providing 83 and 85, the most potent inhibitors of FTase in cells described to date.

  DOI：

  10.1021/jm010531d